Showing results (31-40 of 588) with videos related to
Sort By:
Pageof 59
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B AtkinsThe Lancet. Oncology|October 3, 2009
Resistance to targeted therapy in renal-cell carcinomaBrian I Rini, Michael B AtkinsSeminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B AtkinsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B AtkinsNature Reviews. Clinical Oncology|November 28, 2009
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?Toni K Choueiri, Michael B AtkinsExpert Opinion on Therapeutic Targets|November 4, 2010
New drug targets in Kaposi sarcomaRyan J Sullivan, Liron PantanowitzAmerican Journal of Clinical Dermatology|November 1, 2015
The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted TherapyHugo Akabane, Ryan J SullivanMed (New York, N.Y.)|May 9, 2026
Beyond empiric checkpoint escalation: Insights from KEYVIBE-010Andrew Knight, Ryan J SullivanOncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B AtkinsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Rapid development of hypertension by sorafenib: toxicity or target?Benjamin D Humphreys, Michael B AtkinsPageof 59